Evidence That P-glycoprotein Inhibitor (Elacridar)-Loaded Nanocarriers Improve Epidermal Targeting of an Anticancer Drug via Absorptive Cutaneous Transporters Inhibition
Tài liệu tham khảo
Palmeira, 2012, Three decades of P-gp inhibitors: skimming through several generations and scaffolds, Curr Med Chem, 19, 1946, 10.2174/092986712800167392
Gottesman, 2002, Multidrug resistance in cancer: role of ATP-dependent transporters, Nat Rev Cancer, 2, 48, 10.1038/nrc706
Hashimoto, 2013, ATP binding cassette transporters in two distinct compartments of the skin contribute to transdermal absorption of a typical substrate, J Control Release, 165, 54, 10.1016/j.jconrel.2012.10.011
Iusuf, 2011, P-glycoprotein (ABCB1) transports the primary active tamoxifen metabolites endoxifen and 4-hydroxytamoxifen and restricts their brain penetration, J Pharmacol Exp Ther, 337, 710, 10.1124/jpet.110.178301
Hubensack, 2008, Effect of the ABCB1 modulators elacridar and tariquidar on the distribution of paclitaxel in nude mice, J Cancer Res Clin Oncol, 134, 597, 10.1007/s00432-007-0323-9
Skazik, 2011, P-glycoprotein (ABCB1) expression in human skin is mainly restricted to dermal components, Exp Dermatol, 20, 450, 10.1111/j.1600-0625.2010.01237.x
Ito, 2008, P-glycoprotein (Abcb1) is involved in absorptive drug transport in skin, J Control Release, 131, 198, 10.1016/j.jconrel.2008.08.004
Fujita, 2017, Involvement of the transporters P-gp and BCRP in dermal distribution of the multi-kinase inhibitor regorafenib and its active metabolites, J Pharm Sci, 106, 2632, 10.1016/j.xphs.2017.04.064
Hashimoto, 2017, P-Glycoprotein in skin contributes to transdermal absorption of topical corticosteroids, Int J Pharm, 521, 365, 10.1016/j.ijpharm.2017.02.064
Barcelo, 2006, Paclitaxel for progressive basal cell carcinoma, J Am Acad Dermatol, 54, S50, 10.1016/j.jaad.2005.07.036
Cheung, 2005, AIDS-related malignancies: emerging challenges in the era of highly active antiretroviral therapy, Oncologist, 10, 412, 10.1634/theoncologist.10-6-412
Carvalho, 2017, Co-encapsulation of paclitaxel and C6 ceramide in tributyrin-containing nanocarriers improve co-localization in the skin and potentiate cytotoxic effects in 2D and 3D models, Eur J Pharm Sci, 109, 131, 10.1016/j.ejps.2017.07.023
Chufan, 2016, Drug-protein hydrogen bonds govern the inhibition of the ATP hydrolysis of the multidrug transporter P-glycoprotein, Biochem Pharmacol, 101, 40, 10.1016/j.bcp.2015.12.007
Sintov, 2009, Cutaneous biotransformation of N-(4-bromobenzoyl)-S,S-dimethyliminosulfurane and its product, 4-bromobenzamide, leading to percutaneous penetration enhancement of drugs: initial evidence using hydrocortisone, J Control Release, 133, 44, 10.1016/j.jconrel.2008.09.084
Collier, 1989, Maintenance of skin viability during in vitro percutaneous absorption/metabolism studies, Toxicol Appl Pharmacol, 99, 522, 10.1016/0041-008X(89)90159-2
Thomas, 2014, Stability, cutaneous delivery, and antioxidant potential of a lipoic acid and alpha-tocopherol codrug incorporated in microemulsions, J Pharm Sci, 103, 2530, 10.1002/jps.24053
Cichewicz, 2013, Cutaneous delivery of alpha-tocopherol and lipoic acid using microemulsions: influence of composition and charge, J Pharm Pharmacol, 65, 817, 10.1111/jphp.12045
Alber, 2014, Effects of water activity and low molecular weight humectants on skin permeability and hydration dynamics - a double-blind, randomized and controlled study, Int J Cosmet Sci, 36, 412, 10.1111/ics.12136
Demina, 2005, Relationship between the structure of amphiphilic copolymers and their ability to disturb lipid bilayers, Biochemistry, 44, 4042, 10.1021/bi048373q
Regev, 1999, Membrane fluidization by ether, other anesthetics, and certain agents abolishes P-glycoprotein ATPase activity and modulates efflux from multidrug-resistant cells, Eur J Biochem, 259, 18, 10.1046/j.1432-1327.1999.00037.x
Barta, 2008, Effects of monoglycerides on P-glycoprotein: modulation of the activity and expression in Caco-2 cell monolayers, Mol Pharm, 5, 863, 10.1021/mp800050q
Marupudi, 2007, Paclitaxel: a review of adverse toxicities and novel delivery strategies, Expert Opin Drug Saf, 6, 609, 10.1517/14740338.6.5.609
Kuppens, 2007, A phase I, randomized, open-label, parallel-cohort, dose-finding study of elacridar (GF120918) and oral topotecan in cancer patients, Clin Cancer Res, 13, 3276, 10.1158/1078-0432.CCR-06-2414
Varma, 2003, P-glycoprotein inhibitors and their screening: a perspective from bioavailability enhancement, Pharmacol Res, 48, 347, 10.1016/S1043-6618(03)00158-0
Marquez, 2009, Identification of the efflux transporter of the fluoroquinolone antibiotic ciprofloxacin in murine macrophages: studies with ciprofloxacin-resistant cells, Antimicrob Agents Chemother, 53, 2410, 10.1128/AAC.01428-08
Liu, 2014, P-glycoprotein (P-gp)-mediated efflux limits intestinal absorption of the Hsp90 inhibitor SNX-2112 in rats, Xenobiotica, 44, 763, 10.3109/00498254.2014.891781
Kumar, 2012, Identification of a novel skin penetration enhancement peptide by phage display peptide library screening, Mol Pharm, 9, 1320, 10.1021/mp200594z
Kirjavainen, 1996, Interaction of liposomes with human skin in vitro–the influence of lipid composition and structure, Biochim Biophys Acta, 1304, 179, 10.1016/S0005-2760(96)00126-9
Sane, 2013, Saturable active efflux by p-glycoprotein and breast cancer resistance protein at the blood-brain barrier leads to nonlinear distribution of elacridar to the central nervous system, J Pharmacol Exp Ther, 345, 111, 10.1124/jpet.112.199786